In sum, palonosetron's high affinity and allosteric binding capabilities make it a more efficient receptor antagonist in comparison with agents such as ondansetron and granisetron. Moreover, because palonosetron exhibits positive cooperativity with the 5-HT3 receptor, it may be less likely co be displaced by scrotonin. Palonosetron also results in longer-lasting inhibition of 5-HT3 receptor function compared with ondansetron and granisetron. Together with its longer plasma half-life, these differentiating pharmacologic features may rationalize clinical research evaluating the effectiveness of single-dose palonosetron in preventing CINV throughout the delayed phase.
|Original language||English (US)|
|Number of pages||3|
|Journal||Clinical Advances in Hematology and Oncology|
|Issue number||12 SUPPL. 19|
|State||Published - Dec 1 2007|
ASJC Scopus subject areas